ELLICOTT CITY, Md., May 11, 2011 /PRNewswire/ -- Christine Pierre, president of RxTrials, Inc., today named Adam Chasse vice president of business development. Chasse, who has been head of prime sites for Quintiles, will begin on May 11 and be based in Triangle Park, North Carolina.
"I have collaborated with Adam for 16 years and have admired what he has accomplished personally and for his employer, but what really stands out for me is his integrity. Yes, he brings a global perspective and valuable experience gained by working for the largest contract research organization in the world, but, more importantly, he brings a vision for the future of our organization that is closely aligned with that of our other top managers," said Pierre.
Chasse has served on the board of advisors for the Site Solutions Summit since its inception seven years ago. The Summit is an annual industry meeting organized by RxTrials Institute and focused on research sites' best practices. RxTrials Institute is an RxTrials affiliate.
"Quite frankly he was my first choice; I've been asking him for about five years when he was going to come to the other side and join the sites world," said Pierre with a smile.
"I'm very, very excited because I've always admired RxTrials for its history of delivery and quality, and its forward-thinking approach to improving research practices," said Chasse.
Chasse and Pierre agree that it is becoming increasingly difficult for independent research practices to leverage the economies of scale necessary to be successful. A network of research sites, they say, provides ways to keep sites busier and guarantee high-quality end results while assuring positive patient experiences.
RxTrials has eight research sites located in five states, all of which are located within clinical practices or hospitals. "Adam will provide RxTrials with strategic site development and study placement opportunities focused on our clients' needs," said Pierre.
"RxTrials' vision for expanding opportunities for patients and physicians to take part in important research is identical to mine, so I feel we're a perfect fit," said Chasse.
"It's so expensive to take a drug through the research process, which has been further complicated by the fact that pharma companies are looking at rarer diseases than they were 10 years ago. Therefore, it's more difficult to run a trial in the same period of time partly because it's harder to find enough patients," said Chasse. "On top of that, study designs are getting more complex and investigators are being challenged to recruit more patients while adding procedures and tests. Plus, there is more scrutiny of data by Sponsors and FDA."
"What Sponsors and physicians need is an entity that can help them navigate that process," added Pierre.
"Christine is an innovator and recognized leader in the industry. She has the respect of everyone who knows her. Hers is one of the very few site networks that emerged since 1990 that is still not only around but thriving," said Chasse.
"The deal was recently closed and not yet publically announced and I've already fielded calls from colleagues in the industry. It seems good news travels fast," said Pierre.
RxTrials is a network of premier Investigative Sites based in physician practices and hospitals that conduct Phase II through Phase IV and vaccine clinical research studies. Since 1994, RxTrials has successfully completed more than 1,000 studies and is a strategic partner with leading Sponsors and CROs. Its affiliate, RxTrials Institute, provides professional training, education and consultation, and sponsors the annual Site Solutions Summit.
Interviews and print-quality images of the logo and personnel are available upon request.
|SOURCE RxTrials, Inc.|
Copyright©2010 PR Newswire.
All rights reserved